Lyell Immunopharma to Unveil Breakthroughs at BioConnect 2026

Lyell Immunopharma, Inc. (LYEL) will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026. The session will be led by Lynn Seely, the company’s Principal Executive Officer, President, CEO, and Director. Investors and analysts will hear updates on Lyell’s latest developments in cell therapy research and future plans. Lyell specialises in next-generation cell therapies for both blood cancers and solid tumours. The presentation will focus on key areas, including the CD19/20 space and colorectal cancer. Seely is also expected to make forward-looking statements about the company’s direction.

The company currently has two lead programmes in clinical trials. Ronde-cel, a dual-targeted CAR T-cell therapy for CD19 and CD20, aims to set a new standard in the $3 billion CAR T cell market for large B-cell lymphoma. The second programme targets metastatic colorectal cancer, a growing concern, especially among younger patients. The fireside chat will be moderated by Mitchell Kapoor, a senior biotech analyst at H.C. Wainwright & Co, LLC. The discussion will cover Lyell’s progress and its potential impact on cancer treatment.

The conference presentation will highlight Lyell’s clinical advancements and strategic goals. With two major programmes in development, the company is positioning itself in both hematologic and solid tumour therapies. The session will provide investors with insights into Lyell’s future in the biotech sector.